Clinical Trials Browser

Interventional × Pathologic Complete Response × Bortezomib × Clear all

NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

Phase 3 Unknown

Pathologic Complete Response, Multiple Myeloma

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Phase 2 Completed

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis